{"id":521,"date":"2020-02-05T09:08:19","date_gmt":"2020-02-05T09:08:19","guid":{"rendered":"http:\/\/events.marketsandmarkets.com\/blog\/?p=521"},"modified":"2020-02-05T09:08:19","modified_gmt":"2020-02-05T09:08:19","slug":"speaker-interview-with-sebastien-tabruyn-for-the-4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress","status":"publish","type":"post","link":"https:\/\/events.marketsandmarkets.com\/blognew\/speaker-interview-with-sebastien-tabruyn-for-the-4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress\/","title":{"rendered":"Speaker Interview with Sebastien Tabruyn for the 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress"},"content":{"rendered":"\n

Sebastien Tabruyn holds a PhD in Molecular Biology from the\nUniversity of Liege (Belgium). After 10 years of experience as Project leader\nin renowned international academic research institutes including UCSF\n(California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the\nUniversity of Maastricht (Netherlands), he joined TransCure bioServices in 2013\nas Head of Molecular Biology and Oncology. Sebastien Tabruyn published 30\npeer-reviewed publications in the field of Oncology, Angiogenesis, Inflammation\nand Immunity<\/p>\n\n\n\n

In a recent interview with MarketsandMarkets, Mr. Sebastien Tabruyn shared his thoughts on the current challenges that need immediate attention in the Immuno Oncology Industry, the new opportunities in the field of Imuuno Oncology and the key takeaway point from his presentation at the congress.<\/p>\n\n\n\n

Question:<\/strong> What are the recent advances in the\nimmune-oncology and current challenges that need immediate attention?<\/p>\n\n\n\n

Sebastien Tabruyn:<\/strong> The biggest challenge\ntoday is to predict the efficacy of immunotherapy treatments. Check point\ninhibitors have been proven to be useful, however how to select the patients\nthat will benefit from the treatment remain difficult. Biomarkers are needed as\nwell as a better understanding of how the human immune system interact with the\ntumor.<\/p>\n\n\n\n

Question:<\/strong> What are the new opportunities\nemerging in your field of work?<\/p>\n\n\n\n

Sebastien Tabruyn:<\/strong> The development of\npreclinical models dedicated to understand the complex interaction between the\nfull human immune system and the tumor are key to identify biomarkers and to\ntest efficacy of combo-therapies before going to the clinic.<\/p>\n\n\n\n

Question:<\/strong> What are\nthe key take away points from your presentation topic which will help in\nbuilding the knowledge base of attendees? <\/p>\n\n\n\n

Sebastien Tabruyn:<\/strong> \u00a0TransCure bioServices has develop models that fully recapitulates the functionality of the human immune system. Rather than having one or two human genes (Knock In model), we have here a mouse model that predict treatment efficacy in clinic. All the constituent of the human immune system are present (DC, NK, T cells, B cell, macrophages) and fully functional.<\/p>\n\n\n\n